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SYNOPSIS
Substrate specificity is critically important for enzyme catalysis. In the adrenaline synthesising 
enzyme phenylethanolamine N-methyltransferase (PNMT), minor changes in substituents can 
convert substrates into inhibitors. Here we report the crystal structures of 6 human PNMT 
complexes including the first structure of the enzyme in complex with its physiological ligand R-
noradrenaline: determining this structure required rapid soak methods because of the tendency for 
noradrenaline to oxidize. Comparison of the PNMT:noradrenaline complex with the previously 
determined PNMT:octopamine complex demonstrates that these two substrates form almost 
equivalent interactions with the enzyme and show that octopamine is a valid model substrate for 
PNMT. The crystal structures illustrate the adaptability of the PNMT substrate binding site in 
accepting multi-fused ring systems such as substituted norbornene as well as noradrenochrome, 
the oxidation product of noradrenaline. Our data explain why only a subset of ligands recognised 
by PNMT are methylated by the enzyme: bulky substituents dictate the binding orientation of the 
ligand and can thereby place the acceptor amine too far from the donor methyl group for 
methylation to occur. We also show how the critical Glu185 catalytic residue can be replaced by 
Asp with a loss of only 10-fold catalytic efficiency because protein backbone movements place the 
Asp185 carboxylate almost coincident with the carboxylate of Glu185. Conversely, replacement of 
Glu185 by Gln reduces catalytic efficiency almost 300-fold not only because of the loss of charge 
but also because the variant residue does not adopt the same conformation as Glu185.
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INTRODUCTION
Small molecule methyltransferase (MT) enzymes catalyse the S-adenosyl-L-methionine 
(AdoMet) mediated synthesis and degradation of a wide range of molecules including 
glycine (catalysed by GNMT) [1], histidine (HNMT) [2], creatine (GAMT) [3] and 
catecholamines (COMT, PNMT) [4–6]. Phenylethanolamine N-methyltransferase, or PNMT, 
the enzyme that catalyses the biosynthesis of adrenaline (epinephrine) from noradrenaline 
(norepinephrine) (Figure 1A), is of particular interest because CNS adrenaline is implicated 
in a wide range of physiological and pathological conditions. These include the central 
control of blood pressure [7, 8], pituitary hormone secretion [9, 10], ethanol intoxication 
[11], Parkinson’s disease [12], and the neurodegeneration observed in Alzheimer’s disease 
[13]. To help elucidate the role of CNS adrenaline, potent selective and CNS-active PNMT 
inhibitors have been developed [14–22].
PNMT can accept substrates other than its physiological substrate noradrenaline (1, Figure 
1A), including hydroxyphenylethanolamines and halogen-substituted phenylethanolamines 
(Figure 1B) [4, 23–25]. Although 1 is the physiological substrate of PNMT, its interaction 
with PNMT has not yet been characterized structurally due to its rapid air oxidation to 
noradrenochrome (5, Figure 1B). For kinetic studies, the PNMT model substrate 
phenylethanolamine is preferred (6, Figure 1B, Table 1) [26], but p-octopamine has been 
used (7, Figure 1B, Table 1) [26]. A crystal structure of human PNMT (hPNMT) in complex 
with 7 has been determined previously, and was used to develop a model of the PNMT:1 
complex and to propose the enzyme mechanism [27]. In addition, semi-rigid and rigid 
analogues of substrates and inhibitors of PNMT have been used to develop a structure-
activity profile of the enzyme [27–30]. These studies have shown that 3-trifluoromethyl 
phenylethanolamine (8, Figure 1B) and its rigid analogue anti-9-amino-6-
(trifluoromethyl)benzonorbornene (9, Figure 1B) are both substrates for PNMT (Table 1) 
[31]. However, the position of the aromatic substituent influences recognition and catalysis 
of PNMT substrates because another rigid analogue of 8, anti-9-amino-5-
(trifluoromethyl)benzonorbornene (10, Figure 1B), is not methylated by the enzyme and 
instead inhibits PNMT [28, 31].
Our previous work also highlighted a possible role in catalysis for the PNMT residue 
Glu185 and we had suggested a model whereby, prior to methylation, Glu185 assists in 
deprotonation of the substrate amine via a water [27, 30]. Mutation of Glu185 supports this 
model: replacement with Ala (E185A), Gln (E185Q) or Asp (E185D) has little effect on 
substrate binding (Km is unaffected or increases by 3-fold, Table 1), but by contrast these 
mutations reduce the catalytic efficiency kcat/ Km by 10–20-fold (E185A and E185D) and up 
to ~300 fold (E185Q) (Table 1).
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We sought to determine the molecular basis for these observations by characterising the 
crystal structures of PNMT in complex with (i) the physiological substrate noradrenaline 1, 
(ii) its air-oxidized product noradrenochrome 5, (iii) the 3-trifluoromethyl 
phenylethanolamine substrate 8 and (iv) the anti-9-amino-5-
(trifluoromethyl)benzonorbornene inhibitor 10. In addition, we investigated the structures of 
(v) the E185D and (vi) the E185Q variants of PNMT in complex with 7. Our results support 
the previously proposed model of the hPNMT:1 complex, confirm that octopamine is an 
appropriate model substrate, and reveal that a trifluoromethyl substituent dictates ligand 
orientation, which determines whether the ligand is a substrate or an inhibitor. Further, 
analysis of the hPNMT Glu185 variant structures unexpectedly revealed that large 
conformational changes are induced in the enzyme so that the effects of the mutations 
cannot be explained simply by direct substitution of charge or size of the side chain.
EXPERIMENTAL
Unless otherwise noted, chemicals were purchased from Sigma-Aldrich (St Louis, Missouri, 
USA) as the highest purity available. Compound 8 was purchased from Syntech 
Development Co (New Brunswick, New Jersey, USA). Compounds 9 and 10 were 
synthesised as hydrochloride salts as described previously [28].
Crystallization of hPNMT
C-terminally His6-tagged wt and mutant (E185Q and E185D) hPNMT enzymes were 
expressed and purified as described previously [15, 27]. Protein was concentrated to 50 
mg/ml and mixed with S-adenosyl-L-homocysteine (AdoHcy) at a final concentration of 2 
mM, taking the final protein concentration to 40 mg/mL or 1.25 mM. The protein mixture 
was crystallized by hanging drop vapour diffusion using drops comprising 1.5 µL of protein 
and 1.5 µL of precipitant equilibrated over 400 µL of precipitant solution (4–8% 
polyethylene glycol average molecular weight 6K, 0.25 M LiCl, 0.1 M Na cacodylate pH 
5.5–6.0) [32, 33]. All crystal structures reported here include AdoHcy. Crystals grown with 
no ligand added to occupy the noradrenaline binding pocket were used for compound soaks 
(see below). Crystals of hPNMT:5 and hPNMT:10 were grown by co-crystallisation 
whereby 20–30 mM of the appropriate ligand was added to the hPNMT:AdoHcy mix prior 
to crystallisation. For the complex with 5, we co-crystallised wt hPNMT in the presence of 
racemic noradrenaline, 1, and this was oxidized to noradrenochrome, 5, during the 
crystallisation process.
Crystal Soaks
In some cases, ligand soaks were performed to generate the co-crystal structures. For these 
experiments, crystals of dimensions ~0.25 × 0.25 × 0.25 mm3 were grown in the presence of 
AdoHcy as described above, and transferred to 1 µL of soaking solution. Crystal soak 
solutions were prepared by adding 1 µL of 100 mM of the appropriate ligand dissolved in 
100% dimethylsulfoxide (DMSO) to 9 µL of stabilizing solution so that the final 
concentrations of components were 6.6% polyethylene glycol average molecular weight 6K 
(PEG 6K), 0.3 M LiCl, 0.1 M Na cacodylate pH 5.7, 10 mM ligand and 10% DMSO. In the 
case of 1, which rapidly oxidizes to 5 in air, the ligand solution was prepared immediately 
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before crystal soaking. For the crystal structures complexed with 1, 7, and 8 we chose to 
soak with racemic ligands. Crystals in soak solutions were then re-sealed over the original 
mother liquor solution and incubated at 20°C for 15 min.
X-ray Diffraction Data Measurement
Crystals were cryoprotected by transferring directly from the mother liquor (co-crystals) or 
soak solution (soaked crystals) into mother liquor supplemented with the cryoprotectant 
25% ethylene glycol for 10–15 s. Crystals were then flash-cooled in either a nitrogen gas 
stream at 100 K or by plunging into liquid nitrogen. X-ray diffraction data for hPNMT 
E185Q:7 were measured using the UQ ROCX Diffraction Facility Rigaku FR-E Superbright 
generator with Osmic Vari-Max HF optics and Rigaku Saturn 944 CCD detector. X-ray 
diffraction data for hPNMT E185D:7, wt PNMT:1 and wt PNMT:8 were measured at the 
Australian Synchrotron beamline 3BM1 with MAR 165 CCD detector. X-ray diffraction 
data for wt PNMT:10 were measured using a Rigaku FR-E copper rotating anode generator 
operating at 45 kV, 45 mA with Osmic Confocal Max-Flux™ optics (HiRes2) with an R-
AXIS IV++ imaging plate area detector. Data were processed using Crystal Clear (Rigaku 
Corporation, (c) 1997–2002) or HKL 2000 [34] and phasing was carried out using CNS v1.1 
[35] or PHENIX [36].
Structure Determination
The structures were solved by difference Fourier methods using the structure of PNMT 
(PDB accession code 1HNN with ligands and waters removed [32]) as the starting model. 
The crystal structure contains two molecules of hPNMT in the asymmetric unit (PNMTA 
and PNMTB) [33]. The asymmetric unit was chosen so that the two intermolecular disulfide 
bonds were formed between molecules in the same asymmetric unit [33]. Model building 
was performed using COOT [37] and the structures were refined using either CNS v1.1[35] 
or PHENIX [36]. Coordinates for the ligands were generated using PRODRG [38], restraints 
files were generated using PHENIX [36] and PRODRG [38]. The procedure used was to 
model and refine the structure of the protein first, followed by addition of water molecules, 
then AdoHcy and finally the inhibitor/substrate. The criteria used for including a water 
molecule were: the presence of 2Fo–Fc density at 1 σ and Fo–Fc density at 3 σ and at least 
one possible hydrogen bond within 3.2 Å. R-free analysis using 5 – 10% of reflections was 
used for cross-validation [39]. All of the crystal structure maps revealed density indicative of 
AdoHcy at the cofactor binding site and density consistent with a ligand at the substrate/
inhibitor binding site. Electron density for 1, 7, 8, and 10 was clear and unambiguous in both 
molecules (hPNMTA and hPNMTB) in the asymmetric unit of hPNMT, and consistent with 
the R-enantiomers of 1, 7 and 8 and the S-enantiomer of 10. For the complex of hPNMT 
with 5, electron density corresponding to the ligand was present in hPNMTA and consistent 
with the S-enantiomer. However, the R-enantiomer also makes a reasonable fit so that 
binding of both enantiomers cannot be ruled out. In the second molecule in the asymmetric 
unit, the S-enantiomer of 5 can be modeled into the active site density though the fit is not as 
good as for hPNMTA and Fo-Fc density remains. It is therefore possible that the hPNMTB 
density could correspond to (a) varying binding modes of 5, (b) a mix of 1 and 5, and/or (c) 
a mix of R and S enantiomers. Consequently, our analysis of 5 bound to hPNMT refers only 
to the hPNMTA molecule. Statistics for the crystal structures are presented in Table 2. A 
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figure showing the OMIT electron density for each of the bound inhibitors or substrates is 
provided as supplementary information (Figure S1). Modelling of hPNMT:9 was achieved 
by generating coordinates for 9 using PRODRG [38] and arranging in the hPNMT active site 
using COOT [37]. The trifluoromethyl group of 9 was placed in the position that the same 
group occupies in hPNMT:8 and hPNMT:10, and then small adjustments were made in the 
position of the ring system to minimise unfavourable contacts while maintaining favourable 
interactions. Modelling of hPNMT:AdoMet structures was performed in COOT [37]. 
Coordinates for the model of bound AdoMet were generated using PRODRG [38] and the 
cofactor was then manually positioned in the active site by overlaying equivalent regions 
over the experimentally observed binding mode of AdoHcy. Previously determined 
structures of hPNMT bound to AdoMet were used as a comparison [22].
For structural analysis, all Cα atoms of the hPNMT structures were superimposed using the 
SSM superimposition tool in COOT. Root mean squared deviations (RMSD) for these 
superpositions were in the range 0.2–0.3 Å. Molprobity [40] and CCP4 [41]was used to 
validate the quality of the structures and COOT was used to analyse rotamer probabilities, 
based on frequency of appearance in the PDB [42]. Hydrogen bond (2.5 – 3.2 Å cutoff) and 
hydrophobic interactions (3.8 Å) were identified using the COOT environment distance tool. 
Figures were generated using PyMOL (DeLano, W.L. The PyMOL Molecular Graphics 
System (2002) DeLano Scientific, San Carlos, CA, USA. http://www.pymol.org), using the 
hPNMTA molecule.
RESULTS
Binding Mode of the Physiological Substrate
Although noradrenaline, 1, is the physiological substrate of PNMT, determining the crystal 
structure of PNMT in complex with this substrate has proven challenging because of its 
tendency to oxidize to noradrenochrome, 5. Thus, our attempts to co-crystallise PNMT with 
1 resulted in the structure determination of hPNMT:5.
To overcome this problem, we used crystal soaking methods to minimise the time that 1 is 
exposed to air prior to cryocooling the crystal and data collection. This approach had not 
been investigated previously for hPNMT as it had been thought conformational changes 
might be required for ligands to access the buried binding site [32]. Further, it required that 
we find crystallisation conditions in the absence of an inhibitor. However, we were able to 
generate isomorphous crystals of hPNMT:AdoHcy in the absence of substrate/inhibitor and 
we found that a short soak of 10–15 minutes was sufficient to introduce 1 into the buried 
hPNMT binding pocket.
The structure of hPNMT in complex with 1 reveals that the substrate binding pose is largely 
as predicted from modelling studies [32] and similar to that experimentally determined for 
octopamine 7 (Figure 2A) [27] confirming that 7 is an appropriate model substrate for 
hPNMT studies. Thus, the aromatic ring of 1 is wedged between the sidechains of Phe182 
and Asn39, and the flexible phenylethylamine chain adopts an extended conformation 
(Figure 2B). The interactions between the enzyme and the substrates 1 or 7 are conserved 
(Figure 2B) with the exception that 1 forms additional interactions through its m-hydroxyl 
Drinkwater et al. Page 5
Biochem J. Author manuscript; available in PMC 2018 May 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
group to the side chains of Tyr40 and Lys57. These findings further emphasise the role of 
Lys57 in orienting substrates for catalysis [27, 32].
The overall fold of the enzyme in the hPNMT:5 structure is isomorphous with that of 
hPNMT:1, with an RMSD of 0.3 Å for all Cα atoms. By comparison with 1, the binding 
mode of its oxidation product 5 is flipped by ~180° about the short axis of its fused aromatic 
ring. Additionally, while the R-enantiomer of 1 is observed to bind in the hPNMT crystal 
structure, it is the S-enantiomer of 5 that is modeled. However, a proportion of bound R-
enantiomer of 5 cannot be ruled out. This binding mode places one of the two aromatic 
carbonyl oxygens (5-oxo) in a position similar to that of the β-hydroxyl of 1 in the PNMT 
active site (Figure 2C). The β-hydroxyl of 1 interacts directly with the side chain of hPNMT 
residue Glu219 and—via waters—with the side chains of Asp267 and Asn39 (Figure 2B). 
Arg44 forms part of a hydrogen bonding network with Asp267, Asn39 and an active site 
water (W3) (Figure 2B), like that described for the hPNMT:7 structure [27]. The sidechain 
of Arg44 is within cation-π interaction distance of the benzene ring of 1 (≤ 4.6 Å) [43, 44] 
and is oriented in a pseudo T-shaped geometry that is favoured for such interactions [45]. 
However, the Arg44 guanidinium group is offset from the plane of the benzene ring of 1 so 
that a cation-π interaction is unlikely to contribute significantly to substrate binding.
Surprisingly, the aromatic 5-carbonyl oxygen of 5 (Figure 2D) forms interactions similar to 
those formed to the β-hydroxyl of 1 supporting the suggestion that hPNMT residue Glu219 
may be protonated (unpublished work: P. Georgieva, Q. Wu, M.J. McLeish, F. Himo). The 
6-oxo group of 5 forms water-mediated interactions with the side chain of the catalytic 
residue Glu185 and with the main chain oxygen of Phe182 (Figure 2D). The 3-hydroxyl and 
the indole amine of 5 do not form hydrogen bonds to hPNMT.
hPNMT Substrate versus hPNMT Inhibitor
To investigate why structurally similar ligands are recognised differently by hPNMT – for 
example 9 is a substrate whereas 10 is an inhibitor – we determined the crystal structures of 
hPNMT:8 (Figure 3A, B) and hPNMT:10, and modelled the structure of hPNMT:9. The two 
crystal structures hPNMT:8 and hPNMT:10 are very similar to each other (RMSD 0.3 Å), 
and to hPNMT:1 (RMSD values of 0.3 Å and 0.2 Å, respectively). In the crystal structure of 
hPNMT:8, the substrate 8 has its 3-trifluoromethyl group positioned in a hydrophobic pocket 
formed by the sidechains of Val53, Met258, Val269 and Val272 and forms a hydrogen bond 
with Arg44 (Figure 3A). To achieve these interactions, the aromatic ring of 8 is rotated in the 
active site relative to the aromatic ring of substrate 1 (Figure 3C). However, subtle changes 
in the flexible β-hydroxyethylamine chain allow the acceptor amine to be placed in a similar 
position to that of 1 (Figure 3C). These adjustments to the β-hydroxyethylamine chain lead 
to the displacement of a water molecule that, in the complexes with 1 and 7, mediates an 
interaction between the β-hydroxyl and the acidic sidechain of Asp267. By contrast, in the 
hPNMT complex with 8, the β-hydroxyl forms a direct hydrogen bond with Asp267 and a 
water mediated interaction with the Asn39 sidechain (Figure 3B). The amine of 8, like those 
of 1 and 7, forms no direct interactions with the enzyme, but does form water-mediated 
interactions with the sidechains of Glu185 and Glu219 (Figure 3B).
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In the crystal structure of the hPNMT:10 complex, the 5-trifluoromethyl group occupies a 
position similar to that of the 3-trifluoromethyl group of 8 (Figure 3D) forming hydrophobic 
interactions with side chains of Val53, Met258, Val269 and Val272 and a hydrogen bond 
with Arg44 (Figure 3E). The fused ring adopts a binding mode that is rotated and skewed 
compared with 8 (Figure 3D) and the positions of the amines of 8 and 10 are thus separated 
by almost 1 Å. The amine of 10 forms direct rather than water-mediated hydrogen bonds 
with the side chain of Glu219, in addition to the usual water-mediated hydrogen bond with 
Glu185 (Figure 3F). A water-mediated interaction is also formed between the amine of 10 
and the main chain oxygen of Phe182, similar to that observed between the 6-oxo 
substituent in the noradrenochrome-bound structure hPNMT:5 (Figure 2D, 3F).
We investigated why the binding of 10 does not result in amine methylation by hPNMT (10 
is an inhibitor not a substrate of the enzyme). We modelled the cofactor AdoMet into the 
binding site by adding the donor methyl group to AdoHcy. Previously, we had proposed that 
the angle of attack between the AdoMet donor methyl group and the substrate C–N bond 
influences whether the amine is methylated [27]: substrates had angles of 89–93° and an 
inhibitor had angles of 129–132°. Of the substrates reported in the present work, 1 has 
angles of 100–114° and 8 has angles of 73–84° (Figure 3G). However, the inhibitor 10 has 
values for this angle of 85–89° (Figure 3H), suggesting that it is not the angle of attack that 
prevents hPNMT from methylating 10. We also investigated the distance between the amine 
and the cofactor donor methyl group. In the present work, this distance ranges between 3.8 
and 3.9 Å for the substrates 1 and 8 (Figure 3G), in agreement with our previous work (3.7–
3.9 Å for substrates [27]) and within the expected distance for catalysed methyl transfer 
(3.0–4.0 Å) [46]. By contrast, the distance between the amine of 10 and the AdoMet methyl 
group is 4.4 Å (Figure 3H). We therefore conclude that 10 is an inhibitor and not a substrate 
because its amine is too distant from the cofactor for methylation to occur.
Despite extensive trials, we were unable to measure crystallographic data for the complex of 
hPNMT:9 (a rigid analogue of 8): soaking crystals in solutions containing 9 induced crystal 
disorder or cracking and co-crystallisation resulted in poorly diffracting crystals that gave 
low resolution or streaky diffraction patterns that could not be processed. Instead, the 
structure of hPNMT:9 was modeled from the structures of hPNMT:8 and hPNMT:10 (Figure 
S2, supplementary information). We took the refined molecular structure of 10, and moved 
the trifluoromethyl group from the 5- to the 6-position. The model of 9 was then placed into 
the hPNMT binding site, by positioning the 6-trifluoromethyl group into the same 
hydrophobic pocket occupied by the trifluoromethyl groups of 10 and 8 (Figure S2 panels 
A–C). In this modelled structure, the fit of 9 within the active site is tight: steric clashes are 
formed between 9 and both Tyr35 and Tyr222 (Figure S2 panel B), perhaps explaining why 
crystals crack and diffraction is poor in the presence of this ligand. Presumably, binding of 9 
destabilises the hPNMT crystalline lattice or requires conformational changes in the enzyme 
that disrupt crystal contacts. To minimize unfavourable clashes, we modelled different 
rotameric positions of Tyr35 and Tyr222 sidechains, but this introduced clashes with other 
residues. Nonetheless, conformational changes in Tyr35 and/or Tyr222 may still be possible 
if accompanied by cooperative changes in these other residues, as we have observed for 
other inhibitors [22]. If similar changes occur on binding of the substrate 9, this could 
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explain why it remains an excellent hPNMT substrate (Table 1). Notwithstanding, the model 
of hPNMT:9 gave angle and distance measurements for the amine to AdoMet donor methyl 
group of 3.3 Å and 106°, respectively, consistent with values obtained for other hPNMT 
substrates (Figure S2D).
Glu185 Variants
Our previous studies identified Glu185 as a key catalytic residue of hPNMT: mutation of 
Glu185 significantly reduces the rate of catalysis but has little effect on the affinity of the 
enzyme for the substrate [27] (Table 1). To investigate the molecular basis for these effects, 
we determined the crystal structures of the hPNMT variants E185D and E185Q in complex 
with the model substrate 7. These two point mutations do not affect the overall protein fold, 
in that the crystal structures of the two variants are isomorphous with each other and with 
wthPNMT:7 (RMSD values 0.3 Å in each case). Mutation of the large acidic residue Glu185 
to the smaller acidic residue Asp (E185D) leads to a ~1Å movement of the backbone atoms 
of residue 185 and of nearby residues Thr230 and Val231 compared with the wt structure 
(Figure 4A). Surprisingly, these backbone changes in E185D place the carboxylate group of 
Asp185 almost coincident with the carboxylate of Glu185, and interactions formed to the 
acidic sidechain are conserved between the wt and E185D structures. The backbone changes 
occur with little or no disruption to bound water molecules in the active site or to 
intramolecular interactions of the protein (Figure 4B). However, an interaction between the 
main chain oxygen of Asp185 and the mainchain amine of Val231 is lost and an 
unfavourable interaction is formed between the Asp185 mainchain oxygen and the sidechain 
of Val231, suggesting that binding of substrate to the E185D variant will be less favourable 
than binding to the wt enzyme.
We also investigated the effect of removing the negative charge of Glu185 by determining 
the crystal structure of hPNMT E185Q in complex with the model substrate 7. This mutation 
has been characterised kinetically, and reduces the catalytic activity of the enzyme by ~300 
fold (Table 1) [27]. The structure of hPNMT E185Q:7 (Figure 4C, D) revealed that Gln185 
undergoes a conformational change compared with Glu185. In the wt hPNMT:7 complex, 
the Glu185 sidechain adopts an unusual conformation involving a hydrogen bond to its own 
mainchain nitrogen. This Glu rotamer has a 2% probability of occurrence based on 
frequency of appearance in the pdb. The other carboxylate oxygen forms a hydrogen bond 
with the main chain nitrogen of Ala216, and water mediated interactions with the amine of 7 
and the main chain oxygen of Ile214. These same set of interactions are unfavourable when 
the acidic sidechain is replaced by the amide of a Gln sidechain: the amide nitrogen cannot 
form a hydrogen bond with amides, so the interactions with its own backbone amide or with 
the backbone amide of Ala216 cannot occur. We assume that this is the reason Gln185 
adopts a conformation with a rotamer probability of 1% in the E185Q hPNMT:7 structure 
[42]. This position places its sidechain nitrogen within hydrogen bond distance of the 
mainchain oxygen of Val232, and is not favourable in that it is in close contact with the 
Val231 sidechain, which induces static disorder in Val231 despite a shift of 0.8–1.0 Å in the 
backbone (Figure 4C). Gln185 does form an indirect interaction with the amine of 7, via an 
ordered water located in a position equivalent to that of W1 in the wt hPNMT:7 structure 
(Figure 4D) [27]. Interestingly, the binding position of 7 changes subtly in the structure of 
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E185Q hPNMT:7 in comparison to wt hPNMT:7 (Figure 4A). This change in the binding 
position results in the acceptor amine of 7 moving further than 4 Å from the modeled 
cofactor methyl group, and may also contribute to the reduced catalytic activity of the 
E185Q hPNMT variant.
DISCUSSION
We have reported for the first time the structure of hPNMT in complex with its physiological 
ligand noradrenaline, 1, obtained by using rapid crystal soaking methods. We used the same 
methods to determine the structures of hPNMT:8, hPNMT E185D:7 and hPNMT E185Q:7. 
The results show that ligands can be diffused into hPNMT crystals over 10–15 minutes, 
without generating stresses that lead to crystal cracking or disorder in the diffraction pattern. 
These same soaking methods should therefore be suitable for fragment-screening 
approaches to identify novel inhibitor scaffolds for hPNMT. During efforts to determine the 
structure of hPNMT:1 the structure of hPNMT:5 from co-crystals grown in the presence of 
noradrenaline was also determined. This result confirms that noradrenaline 1 is converted to 
noradrenochrome 5 during the crystallisation experiment and unexpectedly shows that 5 
binds to hPNMT in a reverse orientation: the amine of 5 is located in the same relative 
position of the active site as the catechol hydroxyls of 1, and 6.6 Å from the methylating 
cofactor. Our findings predict that noradrenochrome is not methylated by hPNMT. Oxidation 
of 1 limits its usefulness in kinetic studies of hPNMT. The crystal structure of hPNMT:7 has 
been determined previously by co-crystallisation [27], and the new structure of hPNMT:1 
allowed a direct comparison of the physiological and model substrates. We found that the 
binding of 7 to hPNMT is comparable to that of 1, confirming that 7 is a valid model 
substrate.
Analysis of crystal structures of two trifluoromethyl-substituted ligands of hPNMT, and of 
the modeled structure of a third, showed that this substituent is the driving force in orienting 
these ligands within the active site and thereby determining whether they are methylated by 
hPNMT. These results further confirm the importance of geometry in methylation of ligands 
by hPNMT indicating that the amine should be within 4Å of the donor methyl group and 
have an orientation close to tetrahedral. The structures also explain why Asp267 is important 
for catalysis of 8 but does not affect 9, a rigid analogue of 8 [30]: 8 forms a direct interaction 
with Asp267 through its β-hydroxyl group whereas the modeled structure of the hPNMT:9 
complex suggests that there is no interaction with Asp267.
This research further emphasises previous findings that the binding pocket of hPNMT is 
extraordinarily plastic. Previous studies have shown that the enzyme is capable of movement 
of active site helix α4 and large conformational changes of sidechains (Lys57, Tyr126, 
Met258) to accommodate the binding of some ligands [14, 22]. Our current research shows 
that mutations in active site residues can also lead to structural rearrangements, involving 
both sidechain and mainchain atoms. In the E185D variant, enzyme backbone movements 
are observed that together position the acidic carboxyl group of Asp185 in the same relative 
location as the acidic carboxyl group of Glu185 in the native enzyme. Furthermore, many of 
the same intramolecular interactions involving residue Glu185 are observed in the E185D 
variant, suggesting that these may be important for catalytic activity. The observed reduction 
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in catalytic efficiency of the E185D variant enzyme is likely due to the energetic cost 
required to reposition Asp185 so that it can deprotonate the substrate.
Mutation of Glu185 to Gln causes the most dramatic reduction in catalytic activity of 
hPNMT [30] and this was thought to be due to the loss of the acidic sidechain. However, the 
crystal structure of hPNMT E185Q reveals that the Gln185 sidechain adopts a different 
conformation to that of Glu185 suggesting that the specific conformation of the sidechain 
might also be important for catalytic activity. We were unable to produce hPNMT E185A in 
sufficient quantities for structural studies due to low expression levels [30]. However, the 
fact that the E185A variant retains reasonable catalytic activity compared with E185Q 
suggests that additional factors may be involved. In the conversion of noradrenaline to 
adrenaline, these factors are likely to be that proton transfer is not rate limiting and that in 
the absence of Glu185, the nearby Glu219 residue may be able to accept the proton. 
Mutation of Glu185 to Gln (E185Q) disrupts the hydrogen bonding network between 
residue 185, Glu219, W1 and the substrate, leading to a more dramatic decrease in catalytic 
activity compared with E185A. Overall, our results support an important role for residue 185 
in catalysis and suggest that evolution of hPNMT has given rise to interactions with the 
E185 sidechain, including an internal hydrogen bond, that position it optimally for catalysis. 
These results have wider implications for the interpretation of kinetic data and emphasise the 
value of obtaining structural evidence in combination with kinetic data to provide a 
comprehensive understanding of enzyme activity.
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ABBREVIATIONS
PNMT phenylethanolamine N-methyltransferase
hPNMT human PNMT
wt wild type
hPNMTA molecule A in the asymmetric unit of hPNMT crystals
hPNMTB molecule B in the asymmetric unit of hPNMT crystals
AdoMet S-adenosyl-L-methionine
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AdoHcy S-adenosyl-L-homocysteine
CNS Central Nervous System
CNS v1.1 Crystallography and NMR System version 1.1
SEM standard error of the mean
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Figure 1. Catalytic reaction and chemical structures
A, Schematic of the reaction catalysed by PNMT involving transfer of a methyl group from 
AdoMet, 3, to noradrenaline, 1, forming adrenaline, 2, and AdoHcy, 4. B, Chemical 
structures of substrates and inhibitors described herein.
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Figure 2. Enzyme–ligand interactions and superimpositions of ligand binding positions at the 
hPNMT active site
A, Binding pose of 1 (green) overlayed with 7 (purple). B, hPNMT:1 (green). C, binding 
pose of 5 (pink) overlayed with 1 (green), RMSD 0.3 Å. D, hPNMT:5 (pink).
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Figure 3. Enzyme–ligand interactions and superimpositions of ligand binding positions at the 
hPNMT active site
A, B, Structure of hPNMT:8 (yellow). C, binding pose of 8 (yellow) overlayed with 1 
(green), RMSD 0.3 Å. D, binding pose of 10 (orange) overlayed with 8 (yellow), RMSD 0.3 
Å. E, F, hPNMT:10 (orange). G, binding pose of 8 (yellow) with modelled AdoMet (dark 
grey). H, binding pose of 10 (orange) with modelled AdoMet (dark grey).
Drinkwater et al. Page 16
Biochem J. Author manuscript; available in PMC 2018 May 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. Effect of hPNMT Glu185 variants on residue position and binding pose of 7
A, Structure of wt hPNMT:7 (dark gray) superimposed with E185D hPNMT:7 (light gray), 
RMSD 0.3 Å. B, E185D hPNMT:7 (light gray). C Structure of wt hPNMT:7 (dark gray) 
superimposed with E185Q hPNMT:7 (light gray), RMSD 0.3 Å. D, E185Q hPNMT:7 (light 
gray). Residues 185 and Val231 which exhibit conformational movement are displayed in 
stick representation. Distances are measured between Cα atoms and shown as black dashed 
lines.
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Table 1
Kinetic dataa taken fromb,c,d
Enzyme:substrate Km (µM) kcat (min−1) kcat/ Km (M−1min−1) Ki (µM)
wt:6b 100 ± 4 2.8 ± 0.1 2.8 × 104 -
E185A:6c 100 ± 6 0.17 ± 0.01 1.7 × 103 -
E185D:6 c 320 ± 32 0.85 ± 0.04 2.7 × 103 -
E185Q:6c 100 ± 6 0.01 ± 0.001 99.0 -
wt:7c 5.5 ± 0.6 1.2 ± 0.1 2.2 × 105 -
wt:8b 0.55 ± 0.08 0.50 ± 0.01 9.1 × 105 -
wt:9b 1.5 ± 0.2 0.37 ± 0.04 2.5 × 105 -
wt:10d - - - 13 ± 1
aValues are ± standard error of the mean.
bWu et al [30].
cGee et al [27].
dGrunewald et al [31].
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